These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 599799)

  • 21. [Ambulatory treatment of so-called "essential" arterial hypertension with pindolol. Short-term study].
    Reffo GC; Pitzorno G; Perin S; Forattini C
    Minerva Med; 1980 Jan; 71(1):49-54. PubMed ID: 6101911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of beta-adrenergic blockaders and their combination with an alpha-adrenergic blockader on physical exertion tolerance in patients with hypertension].
    Smirnov GB
    Kardiologiia; 1986 Mar; 26(3):33-6. PubMed ID: 2872358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The cardiotropic effect of the beta receptor blockader Prindolol].
    Fiegel G
    Med Welt; 1975 Oct; 26(43):1989-9. PubMed ID: 1196090
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prindolol in the therapy of arterial hypertension].
    Cocco G; Jerie P
    Boll Soc Ital Cardiol; 1975; 20(11):1449-55. PubMed ID: 1234443
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Adv Clin Pharmacol; 1976; 11():1114-8. PubMed ID: 802071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct 24-hour haemodynamic monitoring after starting beta-blocker therapy: studies with pindolol in hypertension.
    v d Meiracker A; Man in't Veld AJ; van Eck HR; Wenting GJ; Schalekamp MA
    J Hypertens Suppl; 1984 Dec; 2(3):S581-3. PubMed ID: 6100755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of hemodynamic changes in patients with primary arterial hypertension after treatment with a combination of pindolol and clopamide (Viskaldix)].
    Wyrzykowski B; Suchecka-Rachoń K
    Kardiol Pol; 1991; 34(5):286-91. PubMed ID: 1921111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of essential hypertension with prindolol].
    Kuska J; Sledzinski Z; Kokot F
    Wiad Lek; 1977 Apr; 30(7):505-10. PubMed ID: 855327
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of the treatment with propranolol and pindolol on selected hemodynamic parameters in patients with primary arterial hypertension].
    Trojnar R; Markiewicz M; Rymar B; Wysokiński A
    Wiad Lek; 1989 Aug 15-Sep 15; 42(16-18):929-34. PubMed ID: 2701039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study on the effects of pindolol and propranolol on systemic and cardiac haemodynamics in hypertensive patients.
    Velasco M; Morillo J; Ramirez A; Hernández E; Vizcarrondo H; Urbin-Aquintana A; López JM; Medrano G; Hernández-Pieretti O
    Int J Clin Pharmacol Res; 1983; 3(2):95-100. PubMed ID: 6384072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of visken in hypertension associated with ischemic heart disease and nutritional obesity].
    Khomenko VL; Vasiuk IuA; Romashkin AV; Sivkov SI; Mel'nikov AIu; Buskin VD
    Sov Med; 1990; (3):64-7. PubMed ID: 2195673
    [No Abstract]   [Full Text] [Related]  

  • 32. Increase of total body potassium and decrease of exchangeable sodium after long-term treatment with a beta-receptor-blocking agent (prindolol) in essential hypertension.
    Brecht HM; Werner E; Schoeppe W
    Clin Sci Mol Med Suppl; 1976 Dec; 3():551s-554s. PubMed ID: 1071679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aldosteronemia and plasma renin activity in patients with hypertension treated with visken (prindolol)].
    Kuska J; Kokot F; Sledziński Z
    Kardiol Pol; 1977; 20(2):127-35. PubMed ID: 864907
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of the beta-receptor-blocker prindolol on renal hypertension (author's transl)].
    Undeutsch K; Sieberth HG; Meurer KA
    Klin Wochenschr; 1976 Nov; 54(22):1077-84. PubMed ID: 1003866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodynamic effect of long--term treatment with pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm.
    Atterhög JH; Dunér H; Pernow B
    Acta Med Scand; 1977; 202(6):517-21. PubMed ID: 339674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical use of pindolol (Visken) in the treatment of arterial hypertension].
    Lambić IS; Krstić Lj
    Srp Arh Celok Lek; 1977 Feb; 105(2):191-200. PubMed ID: 905885
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of pindolol and nifedipine alone and in combination on haemodynamic parameters/variables in essential hypertension.
    Tsukiyama H; Otsuka K; Yamamoto Y
    J Int Med Res; 1984; 12(3):154-62. PubMed ID: 6734917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of treatment with pindolol (Visken) on hemodynamics in patients with primary hypertension].
    Wyrzykowski B; Suchecka-Rachoń K
    Kardiol Pol; 1986; 29(4):285-91. PubMed ID: 3537436
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of hypertension with the beta-receptor-antagonist pindolol (Viskèn). A comparison with chlorthalidone (Hygroton)].
    Schaffalitzky de Muckadel ; Gyntelberg F
    Ugeskr Laeger; 1973 May; 135(20):971-4. PubMed ID: 4585570
    [No Abstract]   [Full Text] [Related]  

  • 40. [The antihypertensive action of the beta adrenergic blocking agent Visken (pindolol, LB 46) in mild and moderate hypertension].
    Török E; Jávor T; Szám I; Gábor G
    Orv Hetil; 1976 Mar; 117(10):593-8. PubMed ID: 1250586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.